FP-1039

FP-1039 is a recombinant fusion protein consisting of the extracellular domain of fibroblast growth factor receptor 1c (FGFR1c) fused to the Fc region of human IgG1. It acts as a soluble decoy receptor, binding and neutralizing multiple fibroblast growth factors (FGFs) that would otherwise activate FGFRs on tumor cells. By sequestering these ligands, FP-1039 inhibits FGF-mediated signaling pathways involved in tumor cell proliferation and angiogenesis. The drug was developed primarily for oncology indications, including solid tumors such as non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, and endometrial cancers with specific FGFR2 mutations[1][2][3][4][5].

Other names

Fibroblast growth factor ligand trap